Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia

Immunovirological consequences of a switch to a maraviroc/raltegravir dual therapy were analyzed in 16 HIV-infected patients with persistent viral load below 50 copies/ml. At 26-week postswitch, the CD4+/CD8+ ratio decreased and the CD8+ T-cell activation increased. A decrease in classical monocytes was associated with a shift toward a proinflammatory monocyte profile and negatively correlated with ultrasensitive viral load. Thus, this therapeutic switch induced a proinflammatory profile probably driven by a slight loss of virus control.

[1]  S. Vermund,et al.  HIV and Noncommunicable Disease Comorbidities in the Era of Antiretroviral Therapy: A Vital Agenda for Research in Low- and Middle-Income Country Settings , 2014, Journal of acquired immune deficiency syndromes.

[2]  C. Katlama,et al.  Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. , 2014, The Journal of antimicrobial chemotherapy.

[3]  B. Clotet,et al.  Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection , 2014, AIDS.

[4]  M. Fischl,et al.  Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection. , 2013, The Journal of infectious diseases.

[5]  G. d’Ettorre,et al.  Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial , 2013, PloS one.

[6]  S. Moe,et al.  Effects of Switching From Efavirenz to Raltegravir on Endothelial Function, Bone Mineral Metabolism, Inflammation, and Renal Function: A Randomized, Controlled Trial , 2013, Journal of acquired immune deficiency syndromes.

[7]  G. Guaraldi,et al.  HIV-Associated Lipodystrophy: Impact of Antiretroviral Therapy , 2013, Drugs.

[8]  M. Lederman,et al.  The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. , 2013, Blood.

[9]  R. Paredes,et al.  Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. , 2013, The Journal of antimicrobial chemotherapy.

[10]  N. Shaheen,et al.  Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure , 2013, AIDS.

[11]  M. Nelson,et al.  CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection , 2012, Molecular medicine.

[12]  E. Ruiz-Mateos,et al.  Effect of Maraviroc on HIV Disease Progression-Related Biomarkers , 2012, Antimicrobial Agents and Chemotherapy.

[13]  D. Podzamczer,et al.  Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy , 2012, AIDS.

[14]  E. Rosenberg,et al.  Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. , 2011, The Journal of infectious diseases.

[15]  S. Lewin,et al.  Plasma levels of soluble CD14 independently predict mortality in HIV infection. , 2011, The Journal of infectious diseases.

[16]  A. Lazzarin,et al.  Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial , 2011, HIV clinical trials.

[17]  S. Deeks,et al.  HIV infection, inflammation, immunosenescence, and aging. , 2011, Annual review of medicine.

[18]  J. Casanova,et al.  Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors , 2010, Immunity.

[19]  Sarah Palmer,et al.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.

[20]  D. Cooper,et al.  Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials , 2010, The Lancet.

[21]  A. Phillips,et al.  HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity , 2009, BMJ : British Medical Journal.

[22]  T. Perneger,et al.  Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006 , 2008, HIV medicine.

[23]  J. Benito,et al.  CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. , 2004, AIDS research and human retroviruses.

[24]  John W. Mellors,et al.  New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma , 2003, Journal of Clinical Microbiology.

[25]  R. Landmann,et al.  Human monocyte CD14 is upregulated by lipopolysaccharide , 1996, Infection and immunity.

[26]  M. Lederman,et al.  Residual immune dysregulation syndrome in treated HIV infection. , 2013, Advances in immunology.